text_1: 2 例 ( 安慰剂 组 1 例 和 100 mg ubrogepant 组 1 例 ) 被 判定 为 可能 与 试验 治疗 方案 相关 ; 两例 有 混杂 因素 .
  
text_2: two cases ( one in the placebo group and one in the 100 @-@ mg ubrogepant group ) were judged to be possibly related to the trial regimen ; confounding factors were noted in both cases .
  